We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Oncternal Therapeutics

News List

Oncternal Therapeutics Appoints Pablo Urbaneja as SVP, Corporate Development firstwordpharma
July 02, 2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Pablo Urbaneja as Senior Vice President, Corporate Development.
Oncternal gets FDA orphan drug designations for cirmtuzumab to treat MCL and CLL pharmaceutical-business-review
July 06, 2020
Oncternal Therapeutics announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designations of cirmtuzumab for treatment of mantle cell lymphoma (MCL) and for treatment of chronic lymphocytic leukaemia ...